Authors
Latest:
Provisional patent technology filed for cardiovascular disease is for sale or joint ventureCombining sublingual nitroglycerin and aspirin in a tablet or other embodiments could be a significant global market opportunity
Latest:
Pharma 2020: Supplying the FutureRedesigning supply chains could change the shape of bio/pharma
Latest:
OTC and Retail Purchases Round out the View of Patient BehaviorCombining prescription and OTC purchasing patterns gives deeper insights into patient behavior
Latest:
Pharma is under-managing its multi-channel marketing effortsSurvey shows that most digital channels are still experiments with little oversight or follow-through
Latest:
Moving From Big Pharma To A Small Company? You May Be In For A Few SurprisesSponsored by TGaS Advisors
Latest:
Pharma's bread and butter is still made with powderDespite a flurry of specialty pharmaceuticals in innovative formats, traditional powder-based dosages will always be a mainstay
Latest:
Preparing for a serialized supply chainUpcoming California regulatory mandates, and the prospect of a national compliance requirement, are focusing industry attention. Here's what some industry leaders have to say
Latest:
Elevating brand outreach in the age of CovidUsing technology to enable processes, drive cost savings, and deliver better patient outcomes
Latest:
Coordinating payer contracts and direct-to-patient discountingAlthough controversial, patient-focused discounts can play a valuable role in managed-markets programs
Latest:
Simplified approaches to temperature-controlled clinical trial packagingOften, needless cost and complexity--without improving quality and safety--impede cold chain packaging planning
Latest:
Did Industry Fumble the DSCSA Deadline?Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.
Latest:
OPINION: Will Class-Wide REMS Programs Delay New Opioid Approvals?Class-wide opioid REMS will affect four million patients and require cooperation of more than 25 drug manufacturers
Latest:
Not just 'social listening' but social understandingHow new social health analytics tools are supercharging pharma's quest for patient insight
Latest:
Getting Value From End-of-Life-Cycle PharmaceuticalsA review of 84 branded pharmaceutical products with changed ownership as of 2005 shows that many of them can continue to sell, often with much higher prices By Albert I. Wertheimer, PhD, MBA, Temple University, and Ellen F. Loh, BS, MBA, University of Maryland, Baltimore
Latest:
Organizing Your Commercial Compliance ProgramsRegulatory attention has intensified over commercial activities. Here’s what to do to minimize risks and raise compliance levels
Latest:
Monetizing Intellectual Property: Royalties, Revenues and Alternative Sources of CapitalInvestment funds have developed an interest in trading capital for royalties on drug commercializations
Latest:
Supply chains for a patient-centric worldTomorrow's healthcare market, driven by consumer choice and outcomes-driven economics, will create new supply chain models
Latest:
Worldwide, pharma distribution is moving to a serial-coded basisRegardless of how pending US legislation is resolved, manufacturers need to move ahead
Latest:
How to Ensure Successful Design and Implementation of Physician SegmentationThe basic process of defining customer segments and appropriate promotional messaging benefits from a cross-disciplinary approach
Latest:
Outsourced facilities management saves precious financial resourcesLife sciences companies - including mid-market ones - are finding value in an outsourced service
Latest:
A new way to look at the performance of passive cold-chain shipping containersA 'performance curve' chart for containers could simplify the design process
Latest:
Liberating time in the Economy of AttentionPharmaceutical marketing is now operating in a new landscape--the Economy of Attention
Latest:
Supreme Court: reverse payment settlements subject to antitrust scrutinyWhat are the risks of future 'pay for delay' settlements between branded and generic manufacturers?
Latest:
Change is a constant for sales incentive planningSales Compensation Solutions, a new book from ZS Associates, outlines problems and solutions
